Strategic Partners Competitors and Similar CompaniesClear all
Strategic Partners's competitors and similar companies include Pharming Group, Lexicon Pharmaceuticals and CRISPR Therapeutics.
 Strategic Partners Strategic Partners (formerly known as Orphazyme) is a company that forms partnerships with biotech, industrial, commercial, property, and asset management companies. |  Pharming Group Pharming Group is a biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases. |  Lexicon Pharmaceuticals Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology. |  CRISPR Therapeutics CRISPR Therapeutics is a gene editing company focused on developing transformative gene-based medicines for the treatment of serious human diseases. | |
Founding Date | Founding Date 2009 | Founding Date 1988 | Founding Date 1995 | Founding Date 2013 |
Type | Type Public | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations København, DK HQ Chicago, US Newton, US | Locations Leiden, NL HQ Leiden, NL | Locations The Woodlands, US HQ Jersey, JE Atlanta, US Bernards, US Birmingham, US Boston, US Charlotte, US see more | Locations Zug, CH HQ Greater London, GB Cambridge, US San Francisco, US |
Employees | Employees 1 | Employees 404 | Employees 20216% increase | Employees 393 |
Valuation ($) | Valuation ($) 6.8 m | Valuation ($) 590.3 m | Valuation ($) 737.4 m | Valuation ($) 4.2 b |
Financial | ||||
Revenue (est.) | Revenue (est.) kr309k (FY, 2025) | Revenue (est.) $376.1m (FY, 2025) | Revenue (est.) $49.8m (FY, 2025) | Revenue (est.) $3.5m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods $41.6m (FY, 2025) | Cost of goods $274k (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit kr309k (FY, 2025) | Gross profit $341m (FY, 2025) | Gross profit $49.5m (FY, 2025) | Gross profit N/A |
Net income | Net income (kr859k) (FY, 2025) | Net income $2.5m (FY, 2025) | Net income ($50.3m) (FY, 2025) | Net income ($581.6m) (FY, 2025) |
Operating ⚠ | ||||
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 2 (Q3, 2020) | Phase I Trials Products 1 (FY, 2016) | Phase I Trials Products N/A |
Funding | ||||
Total funding raised | Total funding raised $ 58.8m | Total funding raised N/A | Total funding raised $ 244.7m | Total funding raised $ 127m |
For sources of this data, please see the company profile
View Company Profiles
Pharming Group
HQ
Leiden, NL
Employees
404
Pharming Group is a biopharmaceutical company developing protein replacement therapies and precision medicines for the treatment of rare diseases.
View companyLexicon Pharmaceuticals
HQ
The Woodlands, US
Employees
202↑ 16% increase
Lexicon Pharmaceuticals develops therapeutic products for diseases relating to immunology, metabolism, cardiology and ophthalmology.
View companyCRISPR Therapeutics
HQ
Zug, CH
Employees
393
CRISPR Therapeutics is a gene editing company focused on developing transformative gene-based medicines for the treatment of serious human diseases.
View company